Optimal adjunctive haemostat use may reduce length of hospital stay

Optimising Haemostat Use

Surgical bleeding can adversely affect patient outcomes, hospital costs and resources.1–7 
Compared to primary methods of haemostasis alone, optimal use of adjunctive haemostats have been associated with improved patient outcomes and reduced use of hospital resources.8–19

Haemostasis Optimisation Program

Haemostasis Optimisation Program

Haemostasis Optimisation Program (HOP) is designed to improve utilisation of adjunctive haemostats through a systematic approach. It provides guidance on selecting an appropriate adjunctive haemostat for a particular bleeding site and situation.

An Evidence-based Approach to Surgical Bleeding

An Evidence-based Approach to Surgical Bleeding

HOP is based on a large-scale quantitative study on the optimal use of adjunctive haemostats. The study, initiated by Ethicon, involved 11 specialties, 450 surgeons and 7,864 bleeding occasions.16

Educating your surgical teams

Your partner in patient care

The Hemostasis Optimisation Program simplifies the identification of the optimal adjunctive haemostat for each bleeding situation by:

HOP demonstrated in a real-world setting that it can help hospitals achieve substantial cost savings

Real-world Benefits

HOP demonstrated in a real-world setting that it can help hospitals achieve substantial cost savings by shifting to a more cost-effective use of haemostats — without sacrificing effectiveness or affecting patient outcomes.*16 

*Results may vary by specific adjunctive haemostat used. Data based on a US dataset and monetary calculations are in US dollars.

Resources to help your team succeed

Helping you Succeed

We can help you create an implementation plan that is customised to your facility and clinical teams needs. Resources for your teams to communicate education, training, and trial plans to an extended audience are available. For further information, please click below to contact your Ethicon representative.

Haemostasis Optimisation Program Video

References

  1. Corral M et al. Clinicoecon Outcomes Res. 2015;7:409–21. 
  2. Marietta M et al. Transplant Proc. 2006;38(3):812–4. 
  3. Stokes ME et al. BMC Health Serv Res. 2011;11:135. 
  4. Kahn JM et al. Med Care. 2008;46(12):1226–33. 
  5. Dasta JF et al. Crit Care Med. 2005;33(6):1266–71. 
  6. Toner RW et al. Appl Health Econ Health Policy. 2011;9(1):29–37. 
  7. l-Attar N et al. J Cardiothorac Surg. 2019;14(1):64. 
  8. Notarnicola A et al. Blood Coagul Fibrinolysis. 2012;23(4):278–84 
  9. Dancey AL et al. Plast Reconstr Surg. 2010;125(5):1309–17. 
  10. Pan HW et al. Ophthalmology. 2011;118(6):1049–54. 
  11. Molloy DO et al. J Bone Joint Surg Br. 2007;89(3):306–9. 
  12. Sabatini L et al. J Orthop Traumatol. 2012;13(3):145–51. 
  13. Wang GJ et al. J Bone Joint Surg. 2001;83-A(10):1503–5. 
  14. Randelli F et al. Int J Immunopathol Pharmacol. 2013;26(1):189–97. 
  15. Joseph T et al. Eur J Vasc Endovasc Surg. 2004;27:549–52. 
  16. Ferko N et al. Healthcare Purchasing News. 2017;41(11):34–5. 
  17. Levy J et al. Anesth Analg. 2010;110(2):354–64. 
  18. Liu L et al. PLoS One. 2013;8(5):e64261. 
  19. Massin P et al. Orthop Traumatol Surg Res. 2012;98(2):180–5.
     

196038-211116